Overview of the Market:
North America Preclinical in-vivo imaging market has been estimated at USD 292.83 Million in 2018 and is projected to reach USD 371.95 Million by 2023, at a CAGR of 4.90% during the forecast period from 2018-2023. Preclinical in-vivo imaging modalities are very crucial for researchers in observing changes, either at the organ, tissue, cell, or molecular level, responding to physiological or environmental changes. It helps in gaining greater understanding of disease and therapeutic efficacy.
The factors such as development of technologically advanced hybrid preclinical imaging systems such as PET/CT, PET/MRI, and PET/SPECT/CT, and growing acceptance of preclinical imaging as a legitimate drug development tool are the driving the market for Preclinical in-vivo imaging in North America. Declining NIH (National Institutes of Health) funding for life science research is constraining the market growth in this region.
North America market for Preclinical In-vivo Imaging is segmented based on Modality and Reagents. Based on modality, the North America preclinical imaging market is divided into seven major segments, namely, optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems. The preclinical optical imaging systems market includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT imaging systems. The preclinical nuclear imaging systems market comprises micro-PET systems (standalone PET, PET/CT, and PET/MRI), micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI), and tri-modality (PET/SPECT/CT) imaging systems. Bases on the reagents, the North America preclinical imaging market is divided into five segments, namely, optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents market is further sub-segmented as bioluminescent and fluorescent imaging reagents. Likewise, the nuclear imaging reagents market is divided as preclinical PET tracers and SPECT robes.
Geographical Analysis:
Geographically, North America market for Preclinical In-vivo Imaging is segmented into U.S and Canada. North America holds the largest share of the global preclinical imaging market, while, U.S holds the maximum share in North America. The preclinical imaging market in North America is primarily driven by various factors like high volume of preclinical research in this region, easy availability and accessibility of resources, and rising government funding for research and innovation in Canada.
key players in the market:
Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc. are the key players operating in the North America preclinical imaging systems market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Modality
5.1.1 Optical imaging
5.1.1.1 Bioluminescence/fluorescence imaging systems
5.1.1.2 Standalone fluorescence imaging systems
5.1.1.3 Optical + X-ray/optical + CT imaging systems
5.1.2 Nuclear imaging
5.1.2.1 Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
5.1.2.2 Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
5.1.2.3 Tri-modality (PET/SPECT/CT) imaging systems
5.1.3 Micro-MRI
5.1.4 Micro-CT
5.1.5 Micro-ultrasound
5.1.6 Photoacoustic
5.1.7 Magnetic particle imaging systems
5.2 By Reagent
5.2.1 Optical imaging reagents
5.2.1.1 Bioluminescent reagents
5.2.1.2 Fluorescent imaging reagents
5.2.2 Nuclear imaging reagents
5.2.2.1 Preclinical PET tracers
5.2.2.2 Preclinical SPECT probes
5.2.3 MRI contrast agents
5.2.4 Ultrasound contrast agents
5.2.5 CT contrast agents
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Aspect Imaging
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Biospace Lab S.A.
8.3 Bruker Corporation
8.4 LI-COR Biosciences
8.5 Mediso Ltd.
8.6 MILabs B.V.
8.7 MR Solutions Ltd
8.8 PerkinElmer
8.9 TriFoil Imaging
8.10 FUJIFILM VisualSonics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
